Metopiron [2-methyl-1,2-bis-3-pyridyl)-1 -propanone; Su 4885] inhibits 1 1--hydroxylation in the adrenal cortex, and this inhibition is reflected as an increased production of ACTH in the anterior pituitary. It was found by Liddle, Estep, Kendall, Williams, and Townes (1959) Andersson, 1961; Faber, 1961; Gold, Kent, and Forsham, 1961) .
In this paper we report results that obtained when the Metopiron test was applied to patients with rheumatoid arthritis.
Material and Methods
Our rheumatoid group comprised ten patients (3 male, 7 female; average age 53 7 yrs) who had not received steroid treatment for one year before the experiment.
The control group also comprised ten patients (3 male, 7 female; average age 46 0 yrs); the diagnoses of these patients are shown in Table II .
The patients in both groups were hospitalized during the whole experimental period of 6 days. The first, second, fifth, and sixth days were control days when Metopiron was not administered. On the third and fourth days the patients were all given 500 mg. Metopiron orally every 6 hours.
The 24-hr urine was collected and analysed for total 17-hydroxycorticosteroids (17-OHCS) by a modification of the method of Jenkins, Forsham, Laidlaw, Reddy, and Thorn (1955) .
Results
The results of the Metopiron tests for the rheumatoid and control groups are summarized in Tables I and II (opposite).
The differences between the mean values for the two groups are not statistically significant.
A tendency for a delayed reaction in the Metopiron test was evident in the rheumatoid group. The maximal average excretion of total 17-OHCS was recorded in the rheumatoid group on the fifth day (the day following the Metopiron administration), whereas it was recorded on the fourth day (the second day of Metopiron administration) in the control group.
Discussion
Our results seem to indicate that in rheumatoid patients the capacity of the pituitary to produce ACTH, as determined indirectly by the exogenous inhibition of 1 l-3-hydroxylation in the adrenal cortex, does not differ from the capacity in patients with various "non-collagenous" diseases. A tendency was noted in the rheumatoid patients for the response of the pituitary to be delayed, but it was not possible to determine on the basis of our results whether this finding was accidental or not. In an earlier study (Kalliomaki and Rauramo, 1960), it was found that urinary excretion of gonadotrophins is normal in female rheumatoid patients. Signs suggesting the thyrohypophyseal syndrome and an increased extracellular phase in rheumatoid arthritis (Kalliomaki and Holopainen, 1956; Kalliomaki, Kirpila, Koskinen, and Laine, 1958 ) may reflect disturbances in the hypothalamo-pituitary system. It is possible that the delayed response of the anterior pituitary gland in the Metopiron test is also a manifestation of the same kind.
Metopiron has weak diuretic properties (it inhibits aldosterone production). Tables I and II show that the average total output of urine of the rheumatoid patients on the third, fourth, and fifth days was about half a litre larger than the average output in the control group. This may be taken as an indication of the above-mentioned predisposition to an increase in the extracellular fluid phase and to increased oedema in rheumatoid arthritis.
Summary
The variation of the production of ACTH by the pituitary gland when 1 l-fl-hydroxylation in the adrenal cortex is inhibited by Metopiron ("Su4885") has been followed by determining the mean daily excretion of total 17-hydroxycorticosteroids in ten patients with rheumatoid arthritis and in ten control patients with various internal diseases.
The response of the pituitary gland did not differ essentially in the rheumatoid and control groups, although a tendency for the response to be delayed was noted in the patients with rheumatoid arthritis. 
